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Abstract
Background: Persons living with human immunodeficiency virus (PLWH) face an increased burden of chronic
obstructive pulmonary disease (COPD). Repeated pulmonary infections, antibiotic exposures, and immunosuppression
may contribute to an altered small airway epithelium (SAE) microbiome.
Methods: SAE cells were collected from 28 PLWH and 48 HIV- controls through bronchoscopic cytologic brushings.
DNA extracted from SAE cells was subjected to 16S rRNA amplification and sequencing. Comparisons of alpha and
beta diversity between HIV+ and HIV- groups were performed and key operational taxonomic units (OTUs) distinguishing
the two groups were identified using the Boruta feature selection after Random Forest Analysis.
Results: PLWH demonstrated significantly reduced Shannon diversity compared with HIV- volunteers (1.82 ± 0.10 vs. 2.20
± 0.073, p = 0.0024). This was primarily driven by a reduction in bacterial richness (23.29 ± 2.75 for PLWH and 46.04 ± 3.716
for HIV-, p < 0.0001). Phyla distribution was significantly altered among PLWH, with an increase in relative abundance of
Proteobacteria (p = 0.0003) and a decrease in Bacteroidetes (p = 0.0068) and Firmicutes (p = 0.0002). Six discriminative
OTUs were found to distinguish PLWH from HIV- volunteers, aligning to Veillonellaceae, Fusobacterium,
Verrucomicrobiaceae, Prevotella, Veillonella, and Campylobacter.
Conclusions: Compared to HIV- controls, PLWH’s SAE microbiome is marked by reduced bacterial diversity and richness
with significant differences in community composition.
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Background
For the 35 million people living with human immunodefi-
ciency virus (PLWH), antiretroviral therapy (ART) has been
a lifesaving measure. As a result, AIDS-related morbidity
and mortality have decreased markedly; however, aging
with HIV has brought other challenges [1]. For instance,
PLWH are more likely to develop chronic obstructive
pulmonary disease (COPD) [2] and are also more likely to
suffer from severe respiratory symptom burdens even after
adjustment for smoking habits [3]. Although the pathogen-
esis of accelerated COPD in PLWH is poorly understood,
the unique risk for pulmonary infections in this setting
suggests that shifts in the lung microbiome might account
for this phenomenon.
Investigations into the HIV lung microbiome have
yielded interesting insights but no clear consensus. Lozu-
pone et al. found that the abundance of Tropheryma whip-
plei was significantly increased in bronchoalveolar lavage
(BAL) samples of PLWH compared with HIV- control
subjects [4], while a second study by Beck et al. showed
no differences between the two groups [5]. A third study
also evaluating BAL demonstrated that PLWH who had
advanced disease (CD4 cell counts < 500 cells/mm3) had
significantly reduced microbiome diversity when com-
pared to HIV- controls, with diversity starting to return to
normal levels once ART was initiated [6]. While these
studies have offered the first insights into the HIV lung
microbiome, the reliance on BAL fluid may fail to identify
important changes at the specific initial site of injury in
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the pathogenesis of COPD, namely the small airway [7].
The small airway epithelium (SAE) is the first line of
defense against toxins such as cigarette smoke and micro-
bial pathogens. In COPD, remodeling of this layer with
squamous metaplasia, goblet cell hyperplasia, and break-
down of the epithelial barrier junction are critical to injury
development [8]. Moreover, evidence that endotoxins
produced by Staphylococcus aureus and Haemophilus
influenza can damage epithelial barrier function suggests
that an important relationship between the microbiome,
epithelial injury, and COPD may exist [9]. Previous work
by our group identified that within PLWH, the absence of
Pasteurellaceae and Brachybacterium and the presence of
Yersinia species in the SAE could help identify those with
COPD [10]. Our study explores whether significant differ-
ences exist between the SAE microbiomes of PLWH and
uninfected controls.
Methods
Study cohort
PLWH were drawn from the patient population at St.
Paul’s Hospital in Vancouver, Canada, a tertiary care
setting with an active bronchoscopy program and HIV
outpatient clinic. Eligible PLWH were patients who were
undergoing bronchoscopies for clinical purposes (i.e. for
lung masses or nodules or to rule out infection) and
were consented for additional research specimen collec-
tion during the procedure. All subjects were ≥ 19 years
old and provided written informed consent under the
University of British Columbia (UBC) Providence Health
Care ethics protocol H14–03267. HIV- controls were re-
cruited from patients undergoing lung cancer screening
bronchoscopies at the British Columbia Cancer Agency
in Vancouver, Canada. With the exception of seven
HIV-infected patients who were lost to follow-up, all
subjects underwent pre-bronchodilator spirometry ac-
cording to guidelines provided by the American Thor-
acic Society and European Respiratory Society [11].
COPD was defined according to criteria outlined by the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [12].
Sample collection
SAE cells were obtained via bronchoscopic cytologic
brushings. Samples were obtained prior to the collection
of clinical specimens and away from sites of disease as
detected by chest computed tomography (CT) imaging
performed within a month of the bronchoscopy. The
bronchoscope was inserted in the oral cavity into the
trachea and bronchi with minimal use of the suction
channel to avoid contamination. Cytologic brushes were
then directed in the subsegment of interest until resistance
was encountered (in the 5th and 6th generation airways).
Brushings were taken at that site and collected in Cytolyt
(Cytyc, Marlborough, MA) for DNA preservation.
DNA extraction and PCR amplification
DNA was extracted using the Qiagen DNeasy Blood and
Tissue Kit (Qiagen, Toronto, Ontario). Samples were eluted
with 50 ul of distilled water and the DNA concentration
was measured by NanoDrop (ThermoFisher Scientific,
Waltham, MA). All samples were normalized to 12 ng/ul
for downstream experiments. To quantify total bacteria
load in each sample, primers specifying the 293 bp ampli-
con of the 16S rRNA gene were designed using the proto-
col outlined by Sze et a.l [13]. A pooled library consisting
of all the samples with individually labeled indices was
generated using the protocol adopted from a dual-index
sequencing strategy published by Kozich et al. [14]. One
exception to this protocol was that touchdown PCR was
used to amplify the 16S rRNA gene fragments spanning the
V4 region. PCR products were purified with Agencourt
AMPure XP system (Beckman Coulter, Catalog #A63880).
Sequencing was performed on the Illumina MiSeq™ plat-
form (Illumina, Redwood City, CA, USA) with 2 × 250
paired end-read chemistry at the UBC Sequencing and Bio-
informatics Consortium. Further details regarding the PCR
amplification are provided in the supplement.
Microbiome profiling
Sequencing reads were merged, filtered for quality, and
processed using the software mothur v.1.35.1 [15] accord-
ing to the Standard Operating Procedure for MiSeq data
(http://www.mothur.org). The accepted sequences were
clustered into operational taxonomic units (OTUs) using
the 97% identity threshold, and classified using the
Ribosomal Database Project (RDP) Classifier [16] and the
RDP taxonomy training set (http://rdp.cme.msu.edu). To
account for potential sources of contamination, OTUs
observed in the negative extraction controls (sterile water
processed along with samples) were considered contami-
nants and removed from downstream analysis.
Statistical analysis
Alpha diversity measures (Richness, Shannon diversity
index, and Evenness) [17, 18] were obtained using the
Vegan package (V2.3.0) [19] in R (V3.2.0), available at
https://www.r-project.org, and compared according to
COPD or HIV status using the Mann-Whitney U test [18].
Beta diversity analyses based on Bray-Curtis distance matrix
were performed, and differences in microbial communities
between groups were tested by Permutational Multivariate
Analysis of Variance (PERMANOVA) [20]. Nonmetric
Multidimensional Scaling [NMDS] was employed as ordin-
ation method for visualization of Bray-Curtis dissimilarity
values in both groups [21]. Comparisons of relative taxa
abundance (at the phylum level) between groups were
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performed using the Mann-Whitney U test [18]. To identify
the most discriminating OTUs between groups, we
employed a random forest algorithm with Boruta feature
selection [22, 23], and the Vegan package was used to con-
struct abundance heatmaps.
Results
Study cohort
Demographic details of the study cohort are provided in
Table 1. 28 PLWH (7 with COPD and 14 without
COPD, 7 with unknown status) and 48 HIV- controls
(24 with COPD and 24 without COPD) were enrolled.
Males accounted for the majority of the HIV+ cohort
(86%) compared to only half of the HIV- cohort. There
were no statistically significant differences in lung func-
tion and in smoking status between the two cohorts.
Nine (32%) of the PLWH had a detectable plasma HIV
viral load and the mean CD4 count for this group was
419 cells/mm3. Only four (14%) of the PLWH cohort
were not currently on ART.
Total bacterial load
Total 16S rRNA (reflective of total bacterial loads) was
significantly reduced in PLWH compared to the HIV- co-
hort (0.27 ± 1.10 copies/ng DNA vs. 3.25 ± 8.44 copies/ng
DNA, p = 0.0076). However, there were no differences in
total 16S rRNA between HIV+ patients with and without
COPD (p = 0.653) or between HIV- controls with and
without COPD (p = 0.719).
Bacterial diversity
Alpha diversity was assessed using the Shannon diversity
index, richness, and evenness (Fig. 1). There was a
significant decrease in Shannon diversity in the HIV+
compared to the HIV- groups (1.82 ± 0.10 vs. 2.20 ±
0.073, p = 0.0024), driven mainly by a significant reduc-
tion in bacterial richness (23.29 ± 2.75 for HIV+ and
46.04 ± 3.716 for HIV-, p < 0.0001). The difference in
bacterial richness (i.e. overall species count) was confirmed
in a rarefaction curve in which more species were found in
the HIV- group for each random sample compared with
the HIV+ group (Additional file 1: Figure S1). There was
no significant difference in evenness between the two
groups (0.60 ± 0.032 for HIV+, 0.61 ± 0.017 for HIV-,
p = 0.5102). Across the four groups (HIV +COPD+, HIV +
COPD-, HIV-COPD+, and HIV-COPD-), there were
significant differences in Shannon diversity (p = 0.0195) and
richness (p = 0.0006) by Kruskal-Wallis tests. However, this
was entirely driven by differences between the HIV+ and
HIV- groups as there were no significant differences
observed between the COPD+ and COPD- groups. There
was also no significant difference in evenness between the
four groups (p = 0.38). There was a significant direct correl-
ation between FEV1/FVC and Shannon diversity
(p = 0.0095, R = 0.39) in the HIV- group but not within the
HIV+ group (p = 0.1427, R = 0.34). To ensure that the dif-
ferences between HIV+ and HIV- groups was not con-
founded by the clinical indication for bronchoscopy within
the HIV+ group, we compared Shannon diversity and beta
diversity by indication for bronchoscopy, use of inhaled cor-
ticosteroids, cancer diagnosis, and treatment or prophylac-
tic antibiotics. No significant differences were found in any
of these categories (Additional file 1: Figures S2–S6). There
was no correlation between Shannon diversity and CD4
count, nor was there a difference between those with
detectable and undetectable viral loads.
Phyla distribution
A significant increase was observed in the relative abun-
dance of Proteobacteria in PLWH (0.38 ± 0.25 in HIV+ vs.
0.19 ± 0.19 in HIV-, p = 0.0003) (Fig. 2). Decreased abun-
dance of Bacteroidetes (0.23 ± 0.19 in HIV+ vs. 0.35 ± 0.16
in HIV-, p = 0.0068) and Firmicutes (0.18 ± 0.17 in HIV+
vs. 0.33 ± 0.16 in HIV-, p = 0.0002) were found in the HIV
Table 1 Study Cohort Characteristics
PLWH (n = 28) HIV- (n = 48) p-value
Sex
Male (%) 24 (86%) 25 (52%) 0.003
Female (%) 4 (14%) 23 (48%)
Age ± SDa (years) 57.54 ± 11.85 63.00 ± 7.65 0.038
FEV1/FVC (%) ± SDa 70.01 ± 12.62 68.39 ± 15.24 0.498
Smoking Status
Current (%) 12 (43%) 21 (44%) 0.988
Past (%) 14 (50%) 24 (50%)
Never (%) 2 (7%) 3 (6%)
HIV Plasma Viral Load > 50 copies/mL (%) 9 (32%) N/A N/A
CD4 cell count ± SDa (cells/mm3) 419 ± 295 N/A N/A
aSD Standard deviation
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+ group compared to the HIV- group. Figure 3 shows the
distribution of phyla across all four patient groups.
According to a Kruskal-Wallis test, there was a significant
difference in Bacteroidetes (p = 0.0031), Proteobacteria
(p = 0.0013) and Firmicutes (p = 0.0017) across the four
groups. Post-hoc tests were performed using Dunn’s
Multiple Comparison method; the differences observed in
Bacteroidetes and Proteobacteria were driven by the
difference between the HIV+ and HIV- groups in the
COPD- population. The difference observed in Firmicutes
was driven by the difference between the HIV+ and HIV-
groups in the COPD+ population. There was no significant
difference between COPD+ patients and COPD- patients,
irrespective of HIV status.
Microbial compositional analysis
Because there was no difference in alpha diversity between
the COPD+ and COPD- groups, beta diversity analysis
was restricted to comparing the study cohort by HIV
status. Using non-metric multidimensional scaling ana-
lysis, a significant difference in community composition
was detected between the HIV+ and HIV- groups (PER-
MANOVA= 0.001) (Fig. 4). Using Boruta feature selection
with Random Forest analysis, six OTUs were found to be
able to discriminate PLWH from the HIV- group. Figure 5
is a heatmap with yellow representing a lower relative
abundance, red representing a higher relative abundance
and blue representing samples that did not contain such
particular OTUs. OTUs that aligned to Veillonellaceae,
Fusobacterium, Verrucomicrobiaceae and Campylobacter
were not found in PLWH. Moreover, Prevotella and Veil-
lonella were mainly present in HIV- group. These findings
suggest that these six discriminative OTUs were able to
separate PLWH from the HIV- group.
Discussion
In this first comparison of the HIV and non-HIV SAE
microbiome, we discovered that PLWH, had significantly
lower bacterial loads, microbial diversity, and species rich-
ness compared to HIV- controls. While this observation
may seem contrary to what one would expect in a disease
associated with immunosuppression and frequent pulmon-
ary infections, it is in fact consistent with numerous micro-
biome studies comparing disease and non-disease states.
Specifically, regardless of the organ examined, disease states
are often associated with lower microbial diversity, suggest-
ing that a certain degree of diversity is a hallmark of healthy
tissue [24–27]. In the lung, for instance, chronic respiratory
conditions such as cystic fibrosis [28, 29] and COPD [30]
are associated with lower alpha diversity in sputum and
Fig. 1 Shannon diversity a, richness b, and evenness c are shown for PLWH (red) and HIV- subjects (green). Shannon diversity and richness were
both significantly lower in PLWH compared with HIV- subjects. There was no significant difference in species evenness between the two groups
Fig. 2 The relative distribution of phyla between PLWH and HIV-
patients is shown. There was a significant increase in Proteobacteria
(p = 0.0003) and decrease in Bacteroidetes (p = 0.0068) and
Firmicutes (p = 0.0002) in PLWH compared to HIV- patients
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Fig. 3 The distribution of phyla across all four groups is shown. By Kruskal-Wallis tests, there were significant differences between the groups
in Bacteroidetes (p = 0.0031), Proteobacteria (p = 0.0013), and Firmicutes (p = 0.0017). Post-hoc tests by Dunn’s Multiple Comparison method
demonstrated that the differences observed in Bacteroidetes and Proteobacteria were driven entirely by the difference between the HIV + COPD-
and HIV-COPD- groups. However, the difference observed in Firmicutes was driven by the difference between the HIV + COPD+ and HIV-COPD+
groups. There were no significant differences in phyla distribution between the COPD+ and COPD- groups
Fig. 4 Non-metric multidimensional scaling analysis demonstrates a significant difference in bacterial community composition between PLWH
(red) and HIV- subjects (blue) (PERMANOVA = 0.001)
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lung samples. Disease severity in the lung also appears to
track inversely with diversity [30–32]. In similar fashion,
HIV and/or the repeated antibiotic exposures these patients
may have experienced due to frequent infections may lower
SAE diversity. Supporting this theory are the recent find-
ings by Twigg et al. that patients with uncontrolled HIV
have significantly decreased BAL diversity compared with
HIV-uninfected controls [6].
The connection between decreased diversity and dysbio-
sis to COPD pathogenesis is likely multifactorial. In fact,
this relationship may be different between HIV+ and HIV-
groups, with only the latter showing a correlation between
decreased diversity and reduced FEV1/FVC. We were
unable to demonstrate significant microbiome differences
between patients with and without COPD, regardless of
their HIV status. One possible explanation may be that our
study was underpowered to detect any difference. Larger
studies examining the relationship between airflow obstruc-
tion, HIV, and the microbiome are warranted. Targeted
brushings in areas of advanced emphysema compared with
brushings taken from normal lung within the same PLWH
may also help us understand what role the microbiome
may play in COPD pathogenesis. Linking the microbiome
with metabolomic, transcriptomic, and epigenetic modifica-
tions will provide additional clues as to how dysbiosis can
set the stage for progressive airflow obstruction. In a previ-
ous study by our group looking specifically at the SAE
microbiome and its associated transcriptome in HIV [10],
we demonstrated that the abundance of Firmicutes was
negatively correlated with the expression of cilia-related
genes and positively correlated with the expression of im-
mune response genes. Haemophilus species were also nega-
tively correlated with the expression of cilia-related genes.
These genetic pathways could be critical in the pathogen-
esis of accelerated COPD in HIV; however, direct compari-
sons of these relationships to those observed in HIV-
subjects are further required.
Interestingly, the SAE phyla distribution in PLWH was
markedly different from that in HIV- controls in a pattern
that was reminiscent of the differences previously noted be-
tween COPD and non-COPD lungs in an HIV- cohort. We
found that PLWH had an increase in Proteobacteria and
decreases in both Bacteroidetes and Firmicutes compared
with HIV- controls. Similarly, Sze et al. found that lung
tissue from GOLD Stage 4 COPD patients had increased
Proteobacteria and decreased Bacteroidetes and Firmicutes
compared to control lungs [30]. For PLWH, changes in the
abundance of these three phyla may represent an early stage
in the COPD development. Longitudinal studies evaluating
the progression of phyla distribution from healthy to
diseased lungs may help to clarify this association.
A novel aspect of this study was the use of SAE cells to
investigate the unique lung microbiome in HIV. Previous
studies have largely focused on BAL fluid, a useful compart-
ment with which to identify generalized inflammation in
the lung but not one that necessarily provides specific infor-
mation on the pathogenesis of COPD. Profound structural
changes occur in the SAE in COPD, including squamous
metaplasia, ciliary dysfunction, mucous cell hyperplasia,
and the breakdown of apical junctional barriers [8]. Even
prior to the onset of overt COPD, smoking-related changes
in the airway epithelium can be observed. These include
senescent signatures determined by telomere length and
growth differential factor 15 production [33, 34] and gene
expression alterations along immunity and oxidative stress
pathways [35]. SAE changes in HIV have not yet been fully
Fig. 5 In this heat map of OTU abundance, blue indicates a complete absence of the OTU, yellow a lower relative abundance, and red a higher
relative abundance. Six OTUs were found to help distinguish between PLWH and HIV- subjects
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characterized, although two studies have recently shed
greater light. In one study, the presence of X4 tropic HIV
increased both epithelial cell layer permeability and the
expression of pro-inflammatory cytokines [36]. In another
study, HIV was found to bind to airway epithelial basal
cells, resulting in a tissue-destructive phenotype [37].
Whether or not the distinct microbiome of the HIV SAE
plays a role in these processes is certainly a question worth
pursuing in future experiments.
There are a number of limitations noted in our study.
First, contamination by oropharyngeal and environmental
elements is always a concern in a lung microbiome study in
which specimens are obtained via bronchoscopy. This is
particularly true for organs with relatively low microbial
biomass such as the lung. Ideally, reagent samples and oral
and bronchoscope channel washes prior to the procedure
would have helped to identify potential contaminants in
bronchial brushings [38]. Nonetheless, all bronchoscopies
were performed with no suction used upon insertion of the
bronchoscope to avoid oral and large airway contamination.
Second, patients enrolled had other pulmonary concerns,
including lung masses, nodules, and pneumonia. While
these could conceivably pose as confounders, we did not
find significant diversity differences between those with and
without these conditions. This was likely due to the fact
that sample acquisition took place specifically in lobes of
the lung away from clinically important lesions. Further
studies evaluating the microbiome in asymptomatic PLWH
will be necessary moving forward to confirm our findings.
Conclusions
As the demographics of PLWH shift towards older ages,
the spectre of chronic lung diseases looms large and
improved understanding of their pathogenesis in the set-
ting of HIV will become imperative. Dysbiosis in the HIV
SAE marked by significantly reduced microbial diversity
may be one important hallmark or instigator of chronic
lung diseases such as COPD and further explorations of
the microbiome’s role in this process are warranted.
Additional file
Additional file 1: Figure S1. A rarefaction curve is shown for HIV-
subjects (blue) and HIV+ subjects (red). Each line represents a study
subject. Figure S2. Shannon diversity is shown for the HIV+ group
divided by indication for bronchoscopy (n = 18 for lung nodule, n = 10
for pneumonia). Figure S3. Shannon diversity is shown for the HIV+
group comparing those were diagnosed with lung cancer (blue, n = 9)
and those without lung cancer (red, n = 21). Figure S4. Shannon
diversity is shown for the HIV+ group comparing those who were taking
inhaled corticosteroids (blue, n = 4) and those who were not (red, n = 24).
Figure S5. Shannon diversity is shown for the HIV+ group comparing
those who were taking treatment dose antibiotics (blue, n = 8) and
those who were not (red, n = 20). Figure S6. Shannon diversity is
shown for the HIV+ group comparing those who were taking
treatment prophlactic antibiotics (blue, n = 3) and those who were
not (red, n = 25). (DOCX 651 kb)
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